



## **PROTEUS BIOMEDICAL ANNOUNCES LICENSE AND COLLABORATION AGREEMENT FOR SENSOR-BASED PHARMACEUTICALS**

**January 12, 2010**

Proteus Biomedical Inc., a pioneer in intelligent medicine, entered into an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize pharmaceutical products that incorporate Proteus' novel sensor-based technologies in the field of organ transplantation. Novartis also receives certain option rights in cardiovascular and oncology product applications, as well as rights to use Proteus technologies in its clinical development of pharmaceutical products.

Under the terms of the agreement, Novartis will make upfront cash and equity investments in Proteus totaling US\$24 million. Proteus would also receive royalties on worldwide net sales of any Novartis products incorporating its sensor-based technology. Other financial terms were not disclosed.

Proteus has developed an integrated pharmaceutical product platform to personalize, monitor and manage medication treatment and adherence based on novel, sensor-based formulations of pharmaceutical products. Proteus' products are initially focused on cardiovascular disease, tuberculosis and psychiatric disorders and are currently under clinical investigation.

"We believe that Novartis is a global leader in organ transplant drug development and marketing, which makes it an excellent collaborator to advance sensor-based pharmaceutical treatment systems," said Andrew Thompson, president and chief executive officer of Proteus. "We have a great opportunity together to bring a new type of pharmaceutical product to market that could aid patients, their families and physicians to attain maximum adherence with pharmaceutical therapy."

### **About Kaiser Permanente Ventures:**

Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente, makes investments in medical devices, healthcare services and information technology companies. Kaiser Permanente Ventures is dedicated to partnering with entrepreneurial companies to build innovative and enduring businesses that advance the quality and affordability of health care. Since its inception in 1997, Kaiser Permanente Ventures has invested in more than 25 venture-capital backed companies at all stages of development, and contributed organizational expertise, time and resources to the success of these companies. For additional information please visit [www.kpventures.com](http://www.kpventures.com).